The $1.2 million anticancer drug is scientifically known as Akirenzai, an immunotherapeutic drug that is currently used for a variety of hematologic malignancies and has not yet been used for the treatment of small cell lung cancer. Agilensai is a type of cellular immunotherapy drug for chimeric antigen receptor T-cell therapy, or CAR-T therapy, which has been approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma, but there are many challenges to the use of CAR-T therapy for patients with solid tumors such as lung cancer, so its indications do not include small cell lung cancer. Currently, the main treatment for small cell lung cancer is chemotherapy or combined radiotherapy, and commonly used chemotherapy drugs include platinum, etoposide, irinotecan, etc., which can be supplemented by synchronous or sequential radiotherapy according to the condition. Radical resection can also be performed for a few early stage patients. Patients suffering from small cell lung cancer are advised to go to the hospital as early as possible, and under the guidance of professional doctors to carry out corresponding treatments, so as to prolong the survival period of patients as much as possible.